Marisa Wexler, MS,  senior science writer—

Merck announced that its Phase 3 clinical trial HYPERION, which had been testing Winrevair (sotatercept-csrk) in people with recently diagnosed pulmonary arterial hypertension (PAH), will be ended early — a move that will allow all study participants, including those who had been assigned to receive a placebo,…

An imaging technique called 18F-FAPI PET may be able to detect the earliest signs of changes in blood vessel tissues that occur in pulmonary arterial hypertension (PAH), a new study reports. According to researchers, this novel approach, which uses positron emission tomography or PET imaging, may help…

Using in-depth analyses and machine learning, scientists have identified several molecules and genes involved in metabolism that may be diagnostic markers of pulmonary arterial hypertension (PAH). Specifically, their research found five small molecules, or metabolites, and three metabolism-related genes that are tied to a PAH diagnosis. All were “identified…

Sildenafil is generally more effective than bosentan at controlling blood pressure and reducing the need for supplemental oxygen in infants with persistent pulmonary hypertension of the newborn (PPHN), a study shows. The study, “Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn:…

High levels of a small RNA molecule in the blood may be a marker of pulmonary arterial hypertension (PAH) in people with congenital heart diseases, a new study reveals. The study, “Expression and Diagnostic Value of miR-3591-5p in Patients with Congenital Heart Disease-Associated Pulmonary Arterial Hypertension,”…

A Phase 2 clinical trial of TX45, Tectonic Therapeutic’s investigational therapy for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), has begun enrolling eligible patients. The Phase 2 study, called APEX (NCT06616974), is expected to recruit up to 180 adults with PH-HFpEF, ages…

Adding Uptravi (selexipag) to standard-of-care therapy within six months of starting treatment may reduce the risk of hospitalization and disease progression in people with pulmonary arterial hypertension (PAH), a study found. The study, “Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension,” was…

Treatments that target the prostacyclin pathway hold promise as chronic thromboembolic pulmonary hypertension (CTEPH) treatment for patients who aren’t eligible for surgery, but more data is needed to verify the effectiveness of these medications in this type of pulmonary hypertension, according to the authors of a meta-analysis of…

The Pulmonary Hypertension Association (PHA) is fundraising and advocating with a campaign called “Let Your Light Shine” this November for this year’s pulmonary hypertension (PH) awareness month. “The efforts of PHA and the PH community are making a tremendous impact on the lives of those affected by PH,”…

Researchers at Monash University in Australia will use newly granted funding to advance their work on a project that aims to create a novel disease-modifying treatment for pulmonary arterial hypertension (PAH). That funding came from Biocurate, a venture led by the University of Melbourne and Monash that aims…

An upcoming clinical trial will test whether empagliflozin, a drug widely approved to treat diabetes and heart failure, might be able to improve heart health in people with pulmonary arterial hypertension (PAH). The trial will be led by scientists at Cleveland Clinic, with study sites planned at two…

For people with pulmonary arterial hypertension (PAH) both with and without a few co-occurring heart problems, combination therapy with macitentan and tadalafil is similarly effective, according to a new analysis by researchers in the U.S. and Europe. “Initial combination therapy with macitentan plus tadalafil is efficacious in patients with…